Ventas, Inc. filings document the regulatory record of a healthcare real estate investment trust whose common stock trades on the New York Stock Exchange under VTR. The company’s disclosures include Form 8-K reports for operating results, quarterly and annual earnings releases, dividend-related events, material financing agreements and capital markets activity.
Recent filings also cover amendments to credit facilities, registered senior notes issued by Ventas Realty, Limited Partnership and guaranteed by Ventas, ATM sales agreement updates, officer-transition disclosures and proxy materials addressing director elections, executive compensation, shareholder voting matters and governance.
Ventas, Inc. (VTR) reported third-quarter 2026 attributable net income of $0.13 per share, down 7% year over year. Nareit FFO was $1.01 per share, up 15%, and Normalized FFO was $0.99 per share, up 10%. Total Company NOI grew 18% year over year, while Total Company Same-Store Cash NOI grew 11%; SHOP Same-Store Cash NOI grew 16%.
Ventas closed $1.2 billion of senior housing investments during the quarter and $5.2 billion year to date. Through September 30, 2026, it had settled 47.3 million shares under equity forward sales agreements for $3.9 billion in gross proceeds and had $0.8 billion of unsettled agreements, totaling $4.7 billion in equity capital. Net Debt-to-Further Adjusted EBITDA was 4.4x at quarter-end, compared with 5.3x in the year-earlier quarter; liquidity was $4.5 billion. Ventas raised full-year 2026 per-share guidance to $0.64–$0.67 for attributable net income, $3.83–$3.86 for Nareit FFO and $3.87–$3.90 for Normalized FFO, primarily due to investment activity, partially offset by interest rates and foreign exchange.
Ventas, Inc. director Maurice S. Smith was granted 17.8890 direct common-stock units on October 13, 2026, in lieu of director fees, and 66.1050 and 80.6450 direct units on October 15, 2026, as dividend equivalents under two deferral programs. All units are payable solely in common stock.
Ventas, Inc. granted director Sumit Roy 55.1610 common-stock units under its Non-Employee Directors' Cash Compensation Deferral Plan and 80.6450 units under its Non-Employee Directors' Equity Award Deferral Program on October 15, 2026. Both awards reflect dividend equivalents credited for the dividend paid that day. The units are payable solely in common stock and subject to Roy's deferral election and the applicable plan or program terms.
Ventas, Inc. director Joe Vasquez Rodriguez Jr. received a grant of 55 common-stock units on October 15, 2026, reflecting dividend equivalents credited for the dividend paid that day. The units were granted under the Non-Employee Directors' Equity Award Deferral Program and are payable solely in common stock, subject to his deferral election and the program's terms. The $84.86 per-share figure is the grant-date closing price; his direct holdings after the grant were 9,998 shares.
Ventas, Inc. director Marguerite M. Nader acquired 80.645 units of common stock on October 15, 2026, under the Non-Employee Directors' Equity Award Deferral Program. The units were credited as dividend equivalents for the dividend on Ventas common stock paid that day and are payable solely in common stock, subject to her deferral election and the Program's terms. The grant-date closing price was $84.86 per share; her reported direct holdings after the transaction were 23,624.218 shares.
Ventas, Inc. director Roxanne M. Martino received 18 common-stock units on October 13, 2026, in lieu of director fees, and 199 units on October 15, 2026, as dividend equivalents under the company's Non-Employee Directors' Cash Compensation Deferral Plan. The units are payable solely in common stock. The grant-date closing prices were $83.85 and $84.86 per share, respectively.
Ventas, Inc. director Matthew J. Lustig received grants of 238.848 common-stock units under the Non-Employee Directors' Cash Compensation Deferral Plan and 80.645 units under the Non-Employee Directors' Equity Award Deferral Program on October 15, 2026. Both grants arose from dividend equivalents credited for the dividend paid that day; the units are payable solely in common stock and subject to his deferral election and the applicable plan or program. The reported $84.86 per share is the stock's closing price on the grant date.
Ventas, Inc. director Michael J. Embler received 81 common-stock units on October 15, 2026, as dividend equivalents under the Non-Employee Directors' Equity Award Deferral Program. The units are payable solely in common stock and subject to his deferral election and the Program. His direct common-stock holdings after the grant were 19,354 shares. The reported $84.86 per-share amount was the stock's closing price on the grant date.
Ventas, Inc. director Melody C. Barnes was granted 80.645 common-stock units on October 15, 2026, through the Non-Employee Directors' Equity Award Deferral Program, reflecting dividend equivalents credited for the dividend paid that day. The units are payable solely in common stock and subject to the terms of her deferral election and the Program. Her direct holdings after the grant were 35,459 shares. The $84.86 per-share figure is the closing price on the grant date.
Ventas, Inc. director Maurice S. Smith acquired 18 common-stock units on October 6, 2026, under the Non-Employee Directors’ Cash Compensation Deferral Plan in lieu of director fees. The units are payable solely in common stock and are subject to Smith’s deferral election and the plan’s terms. The reported $81.86 per-share figure is the issuer’s closing price on the grant date. Smith held 31,807 shares directly following the award.